CAMBRIDGE, Mass., December 8, 2022 – Cerberus Therapeutics, Inc., an early-stage biotechnology company focused on development of proprietary nanobody-based platforms to create novel immunotherapeutics, announced today the closing of seed investment of $4 million from Sherpa Healthcare Partners. The proceeds will enable Cerberus to advance its antigen specific tolerance program, currently in preclinical development.
“Unlike traditional approaches to suppress immune responses, Cerberus’ antigen specific tolerance technology engages all types of professional antigen presenting cells to activate the complex immune networks, leading the system to re-wire itself and potentially presenting a cure to many devastating autoimmune diseases,” said Novalia Pishesha, Ph.D., Chief Executive Officer and Co-Founder of Cerberus Therapeutics. “The seed investment from Sherpa will allow Cerberus to advance its pre-clinical work in multiple sclerosis, rheumatoid arthritis, and AAV tolerance approach.”
About Cerberus Therapeutics
Founded in 2021 by Novalia Pishesha, Ph.D., Prof. Hidde Ploegh, Ph.D. and Prof. Harvey Lodish, Ph.D., Cerberus Therapeutics’ nanobody-based technology comprises two distinct platforms: one that targets autoimmunity and one aimed at infectious disease. Leveraging the unique biochemical properties and excellent targeting capabilities of alpaca-derived nanobodies (variable domains of heavy chain-only antibodies), Cerberus’ technology has the potential to reset the immune system and have it rewire itself for therapeutic gain.
Cerberus Contact:
Xiaohong Sang
617-416-6228
xsang@cerberustx.com